TNFRSF1B and neoplasm: TNFR2-humanized mice were subcutaneously inoculated with MC38 tumor cells and treated with antibodies for 35 days when tumors reached 80 mm3 to allow comparison of the effects of Nanobody-161 and OPI-SBT002e.